Golgi protein 73 as a biomarker of hepatocellular cancer: Development of a quantitative serum assay and expression studies in hepatic and extrahepatic malignancies (Hepatology (2009) 49, (1421-1423) DOI: 10.1002/hep.22994);Golgi protein 73 as a biomarker of hepatocellular cancer: Development of a quantitative serum assay and expression studies in hepatic and extrahepatic malignancies

Hepatology

Volumn 49, Issue 5, 2009, Pages 1421-1423

  Fimmel, Claus J ^a   Wright, Lorinda ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; AUTOANTIBODY; BIOLOGICAL MARKER; GOLGI PROTEIN 73; MEMBRANE PROTEIN; MESSENGER RNA; UNCLASSIFIED DRUG; GOLM1 PROTEIN, HUMAN; TUMOR MARKER;

ACUTE HEPATITIS; AMINO ACID SEQUENCE; BREAST CANCER; CANCER GRADING; CELLULAR DISTRIBUTION; CHRONIC HEPATITIS; DIGESTIVE SYSTEM CANCER; DISEASE MARKER; EDITORIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FUCOSYLATION; GOLGI COMPLEX; HEPATITIS B; HEPATITIS C; HUMAN; IMMUNOREACTIVITY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; PROTEIN URINE LEVEL; QUANTITATIVE ASSAY; SENSITIVITY AND SPECIFICITY; STELLATE CELL; THYROID CANCER; WESTERN BLOTTING; BILE DUCT TUMOR; BLOOD; LIVER ADENOMA; LIVER TUMOR; METABOLISM; NODULAR HYPERPLASIA; NOTE;

ADENOMA, LIVER CELL; BILE DUCT NEOPLASMS; CARCINOMA, HEPATOCELLULAR; FOCAL NODULAR HYPERPLASIA; HUMANS; LIVER NEOPLASMS; MEMBRANE PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 66149121805     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.23081     Document Type: Erratum

References (20)

1. Kladney RD, Bulla GA, Guo L, Mason AL, Tollefson AE, Simon DJ, et al. GP73, a novel Golgi-localized protein upregulated by viral infection. Gene 2000;249:53-65.
2. Kladney RD, Cui X, Bulla GA, Brunt EM, Fimmel CJ. Expression of GP73, a resident Golgi membrane protein, in viral and nonviral liver disease. HEPATOLOGY 2002;35:1431-1440.
3. Iftikhar R, Kladney RD, Havlioglu N, Schmitt-Graff A, Gusmirovic I, Solomon H, et al. Disease- and cell-specific expression of GP73 in human liver disease. Am J Gastroenterol 2004;99:1087-1095.
4. Block TM, Comunale MA, Lowman M, Steel LF, Romano PR, Fimmel C, et al. Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans. Proc Natl Acad Sci U S A 2005;102:779-784.
5. Marrero JA, Romano PR, Nikolaeva O, Steel L, Mehta A, Fimmel CJ, et al. GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J Hepatol 2005;43:1007-1012.
6. Mao YL, Yang HY, Xu HF, Sang XT, Lu X, Yang ZY, et al. Significance of Golgi glycoprotein 73, a new tumor marker in diagnosis of hepatocellular carcinoma: A primary study [in Chinese]. Zhonghua Yi Xue Za Zhi 2008; 88:948-951.
7. Block TM, Marrero J, Gish RG, Sherman M, London WT, Srivastava S, et al. The degree of readiness of selected biomarkers for the early detection of hepatocellular carcinoma: Notes from a recent workshop. Cancer Biomark 2008;4:19-33.
8. Bachert C, Fimmel C, Linstedt AD. Endosomal trafficking and proprotein convertase cleavage of cis Golgi protein GP73 produces marker for hepatocellular carcinoma. Traffic 2007;8:1415-1423.
9. Puri S, Bachert C, Fimmel CJ, Linstedt AD. Cycling of early Golgi proteins via the cell surface and endosomes upon lumenal pH disruption. Traffic 2002;3:641-653.
10. Gu Y, Chen W, Zhao Y, Chen L, Peng T. Quantitative analysis of elevated serum Golgi protein-73 expression in patients with liver diseases. Ann Clin Biochem 2009;46:38-43.
11. Sangiovanni A, Romeo R, Prati GM, Manini MA, Iavarone M, Ronchi G, et al. Serum expression of lectin reactive alpha-fetoprotein, des-gammacarboxy prothrombin, golgi protein-73 antigen and antibody, for the diagnosis of hepatocellular carcinoma [Abstract]. HEPATOLOGY 2007; 46(Suppl):406A.
12. Norton PA, Comunale MA, Krakover J, Rodemich L, Pirog N, D'Amelio A, et al. N-linked glycosylation of the liver cancer biomarker GP73. J Cell Biochem 2008;104:136-149.
13. Riener M-O, Stenner F, Liewen H, Soll C, Breitenstein S, Pestalozzi BC, et al. HEPATOLOGY 2009;49:1602-1609.
14. Anderson NL, Anderson NG. The human plasma proteome: History, character, and diagnostic prospects. Mol Cell Proteomics 2002;1:845-867.
15. Lu Y, Yi Y, Liu P, Wen W, James M, Wang D, et al. Common human cancer genes discovered by integrated gene-expression analysis. PLoSONE 2007;2:e1149.
16. Wei S, Dunn TA, Isaacs WB, De Marzo AM, Luo J. GOLPH2 and MYO6: Putative prostate cancer markers localized to the Golgi apparatus. Prostate 2008;68:1387-1395.
17. Varambally S, Laxman B, Mehra R, Cao Q, Dhanasekaran SM, Tomlins SA, et al. Golgi protein GOLM1 is a tissue and urine biomarker of prostate cancer. Neoplasia 2008;10:1285-1294.
18. Kristiansen G, Fritzsche FR, Wassermann K, Jager C, Tolle A, Lein M, et al. GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: Implications for tissue-based diagnostics. Br J Cancer 2008;99: 939-948.
19. Fritzsche FR, Riener MO, Dietel M, Moch H, Jung K, Kristiansen G. GOLPH2 expression in renal cell cancer. BMC Urol 2008;8:15.
20. Li H, Wetten S, Li L, St Jean PL, Upmanyu R, Surh L, et al. Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease. Arch Neurol 2008;65:45-53.